Sign In
Buy GTBP
$0.294
-0.0143 (-4.65%)
At Close: Jul 31, 2026
EXCLUSIVE: GT Biopharma Plans 2026 Trial For New Cancer Treatment
08:01am, Thursday, 15'th Jan 2026
GT Biopharma Inc. (NASDAQ: GTBP) on Thursday said it submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) in December 2025 for GTB-5550 TriKE for soli
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge
06:00am, Wednesday, 24'th Dec 2025
VANCOUVER, British Columbia, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Equity Insider News Commentary - The U. S. oncology market is projected to surge from $81 billion in 2025 to $212 billion by 2034[1], dri
Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030
07:44am, Friday, 19'th Dec 2025
Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC , Dec. 19, 2025 /PRNewswire/ -- USA News Group News Commentary – The recent FDA approval in November of the first bispecific antibody combinati
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points
12:20pm, Thursday, 04'th Dec 2025
/PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells
GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials
08:00am, Wednesday, 19'th Nov 2025
NAPLES, FL / ACCESS Newswire / November 19, 2025 / Patients battling aggressive blood cancers face limited treatment options and uncertain outcomes. Scientists have increasingly turned to the body's o
GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update
09:00am, Friday, 14'th Nov 2025
Phase 1 trial evaluating GTB-3650 TriKE ® for relapsed or refractory (r/r) CD33 expressing hematologic malignancies continues to actively enroll with the next update anticipated in Q1 2026
GT Biopharma Reports Second Quarter 2025 Financial Results
04:05pm, Thursday, 14'th Aug 2025
SAN FRANCISCO, CALIFORNIA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeuti
GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2
07:00am, Monday, 11'th Aug 2025
The first patient in Cohort 3, the fifth patient in the trial, has completed the first week of cycle 1 following the successful safety review of Cohort 2 with no safety or tolerability issues observed
GT Biopharma Appoints New Member to its Board of Directors
09:00am, Friday, 13'th Jun 2025
SAN FRANCISCO, CALIFORNIA, June 13, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeuti
Following the formal safety review of Cohort 1, no safety or tolerability issues were observed, allowing the company to move forward with Cohort 2.
GT Biopharma Appoints New Member to its Board of Directors
07:00am, Wednesday, 14'th May 2025
SAN FRANCISCO, CALIFORNIA, May 14, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutic
GT Biopharma Announces Exercise of Warrants
02:00pm, Tuesday, 25'th Feb 2025
SAN FRANCISCO, CALIFORNIA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeuti
GT Biopharma Reports Third Quarter 2024 Financial Results
04:00pm, Thursday, 14'th Nov 2024
SAN FRANCISCO, CALIFORNIA, Nov. 14, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeuti
GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
09:15am, Thursday, 26'th Sep 2024
SAN FRANCISCO, CALIFORNIA, Sept. 26, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeut
GT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024
09:15am, Tuesday, 24'th Sep 2024
SAN FRANCISCO, CALIFORNIA, Sept. 24, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeut
